Marlborough, United Stateswww.hologic.com/
Invested through
  • Triodos Future Generations Fund
  • Triodos Impact Strategy Fund - Defensive
  • Triodos Impact Strategy Fund - Balanced
  • Triodos Impact Strategy Fund - Offensive
  • Triodos Impact Strategy Fund - Dynamic
Asset ClassesListed equity
Impact strategyImpact Equities and Bonds
ISIN codeUS4364401012
Industry groupHealth Care Equipment & Services
Aligned with SDGs
  • Good health and well-being

Founded in 1985, US company Hologic develops, manufactures, and supplies premium diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. The company operates in four product segments: Diagnostics (54.9% of total revenue in 2020, screening and diagnosis of human diseases), Breast Health (17.8%, solutions for breast cancer care for radiology, pathology, and surgery), GYN Surgical (9.9%, devices for the treatment of abnormal uterine bleeding, incision-less removal of fibroids, polyps, and other pathology within the uterus), and Skeletal Health (1.5%, devices to evaluate bone density and perform body composition assessments). The remaining 14.5% of revenues generates from ongoing service, installation, and repair of its products.

Investment rationale

The World Health Organization (WHO) assesses sexually transmitted infections (STIs) and breast cancer as health issues with profound impact worldwide, especially in low- and middle-income countries where diagnostic tests are largely unavailable. In higher-income countries where testing is available, it is often expensive and geographically inaccessible, and patients often need to wait a long time to receive results which leads to impeded follow-ups and incomplete care or treatment. Breast cancer is the top cancer in women worldwide, with its incidence increasing in the developing world due to higher life expectancy, increase urbanization and adoption of western lifestyles. Early detection improves outcomes and survival rates.

Hologic’s products focus on women care and are key in diagnosing and handling several diseases, from STIs to breast cancer. The company has several initiatives to improve accessibility such us offering its products in resource-limited countries in Africa at a reduced price. Hologic developed a Global Women’s Health Index which tracks women’s health over time and believes it will help improve equity and expand access to life-saving medical treatments in places around the world where it is needed most. Hologic contributes both directly and indirectly to the welfare of children. Directly because it has tests to detect pre-term birth risks. Indirectly because the World Bank states that research has shown that many maternal illnesses and lifestyle behaviour also affect children. Therefore, healthy mothers are key to the health and well-being of children.